# TOTEM: Switch From Other Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to Once Daily Truvada

> **NCT00323492** · PHASE4 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 92 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Truvada
- **DRUG:** Current HAART regimen

## Key facts

- **NCT ID:** NCT00323492
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-09
- **Primary completion:** 2007-07
- **Final completion:** 2008-03
- **Target enrollment:** 92 (ACTUAL)
- **Last updated:** 2010-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00323492

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00323492, "TOTEM: Switch From Other Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to Once Daily Truvada". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00323492. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*